Graham Capital Management L.P. Purchases New Position in SI-BONE, Inc. (NASDAQ:SIBN)

Graham Capital Management L.P. bought a new position in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 35,487 shares of the company's stock, valued at approximately $498,000. Graham Capital Management L.P. owned 0.08% of SI-BONE as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Mainstream Capital Management LLC acquired a new position in SI-BONE during the 4th quarter valued at about $53,000. R Squared Ltd bought a new stake in shares of SI-BONE in the 4th quarter worth approximately $73,000. KLP Kapitalforvaltning AS bought a new stake in shares of SI-BONE in the 4th quarter worth approximately $97,000. Proficio Capital Partners LLC bought a new stake in SI-BONE during the 4th quarter valued at $155,000. Finally, AlphaQuest LLC grew its stake in SI-BONE by 13,950.6% during the fourth quarter. AlphaQuest LLC now owns 11,662 shares of the company's stock valued at $164,000 after acquiring an additional 11,579 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors.

Insider Transactions at SI-BONE

In other news, CFO Anshul Maheshwari sold 4,937 shares of the company's stock in a transaction dated Wednesday, May 7th. The shares were sold at an average price of $17.00, for a total transaction of $83,929.00. Following the completion of the transaction, the chief financial officer now directly owns 265,356 shares of the company's stock, valued at approximately $4,511,052. This represents a 1.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of the company's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the transaction, the senior vice president now directly owns 244,878 shares of the company's stock, valued at approximately $3,462,574.92. This trade represents a 1.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 55,153 shares of company stock worth $935,040. Insiders own 4.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on SIBN shares. Truist Financial raised their price target on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price target on shares of SI-BONE in a report on Tuesday, May 6th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th.

SI-BONE Price Performance

NASDAQ:SIBN traded down $0.34 during midday trading on Monday, hitting $19.45. The company had a trading volume of 663,194 shares, compared to its average volume of 375,116. The company has a market capitalization of $828.86 million, a PE ratio of -21.14 and a beta of 0.82. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. SI-BONE, Inc. has a 52-week low of $11.70 and a 52-week high of $20.07. The stock's fifty day moving average price is $14.83 and its 200-day moving average price is $15.04.

SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $47.29 million for the quarter, compared to analysts' expectations of $45.13 million. As a group, research analysts expect that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.